NetScientific PLC Lawrence Cohen appointed as CEO of Glycotest Inc. (1865J)
16 Dezembro 2015 - 5:00AM
UK Regulatory
TIDMNSCI
RNS Number : 1865J
NetScientific PLC
16 December 2015
NetScientific appoints diagnostics leader Lawrence Cohen
as CEO of Glycotest Inc.
London, UK - 16 December 2015 - NetScientific plc (AIM: NSCI,
"NetScientific" or the "Group"), the transatlantic biomedical and
healthcare technology group, today announces the appointment of
Lawrence 'Larry' Cohen as CEO of its portfolio company, Glycotest,
effective from 4 January 2016.
Glycotest is a molecular diagnostics company commercializing
clinical laboratory testing services which reduce mortality and
increase survival for patients at risk of liver cancers and
fibrosis-cirrhosis. Larry's appointment will help accelerate the
development and commercialisation of Glycotest's novel non-invasive
blood tests.
Larry brings over 30 years' experience in the medical device and
diagnostics sector. His most recent role was CEO of Exalenz
Bioscience, a medical device company for the diagnosis and
management of digestive tract and liver diseases. Previously, Larry
worked in several senior level roles within the diagnostics sector,
including as CEO of SenGenix, CEO of Hemosense and President of
International Technidyne Corp. which grew 3 times under his
leadership. Formerly, Larry was VP marketing and sales for global
diagnostic companies including Beckman Instruments, Fisher Medical
Group and Ortho Clinical Diagnostics, a Johnson & Johnson
company.
Francois Martelet, Group CEO of NetScientific, commented: "Larry
Cohen is a seasoned executive in the world of diagnostics, who will
be instrumental in driving the delivery of Glycotest's novel tests.
Our focus as a Group is to move our portfolio companies to
commercialisation. Larry's appointment follows on from our recent
appointment of Gene Walther as CEO of Vortex BioSciences, both will
play a crucial part in our Diagnostics franchise once they start in
their roles on 4 January 2016."
Larry Cohen said: "Glycotest has an important diagnostic testing
capability which has the potential to make a significant impact on
patients' lives. NetScientific and the Glycotest team have
developed an extraordinary test; it is my aim to continue this
momentum by bringing this test to the market."
- Ends -
Contact Details
NetScientific Tel. +44
(0) 20 3514 1800
François R. Martelet,
M.D., CEO
Peter Thoms, CFO
Investec (NOMAD and broker)
Gary Clarence/Daniel Adams
Tel + 44 (0) 20 7597 4000
Instinctif Partners Tel.
+44 (0) 20 7457 2020
email: netscientific@instinctif.com
Melanie Toyne-Sewell /
Jayne Crook / Rosanna
Forrest
About NetScientific
NetScientific is a biomedical and healthcare technology group
that funds and develops technologies that offer transformative
benefits to people's lives and society through improved diagnosis,
prognosis and treatment.
For more information, please visit the website at
www.netscientific.net.
About Glycotest
Glycotest is a molecular diagnostics company commercializing
clinical laboratory testing services to reduce mortality and
increase survival for patients at risk for liver cancers and
fibrosis-cirrhosis. Glycotest employs unique non-invasive blood
tests based on proprietary serum biomarkers, biomarker panels and
assay methodology that exploit novel sugar-based disease signal
chemistry. Glycotest initially will make its testing services
available to physicians who care for at-risk patients to help them
identify those likely to have curable early-stage disease.
Ultimately Glycotest intends to develop its tests into tools for
prediction of therapeutic response and clinical outcome.
Glycotest was founded in 2012 on technology that originated at
the Baruch S. Blumberg Institute (the Hepatitis B Foundation's
research organization) and Drexel University College of Medicine in
the laboratories of Dr. Timothy Block and Professor Anand Mehta.
www.glycotest.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDGBDDUSBBGUU
(END) Dow Jones Newswires
December 16, 2015 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024